David Sykes, M.D., Ph.D.
David Sykes is a hematology/oncology fellow at the Dana-Farber Cancer Institute/MGH combined fellowship program. His primary interest is working towards understanding more about acute myeloid leukemia (AML). Adult AML has a poor overall survival rate of approximately 25%. The mutations that lead to AML involve both mutations that lead to uncontrolled growth and mutations that lead to incomplete maturation. David's research will focus on understanding why the leukemic cells do not mature normally, and on identifying new drugs that can promote maturation and be used in the treatment of patients with AML.
David was an undergraduate at the University of Alberta in Edmonton, Canada where he received his B.S. in biochemistry. He was accepted in to the Medical Scientist Training Program at the University of California in San Diego and did his Ph.D. research in the lab with Dr. Mark Kamps. David completed his clinical training in internal medicine at the Massachusetts General Hospital as well as an extra year as chief medical resident.